5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses
Indication: Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
Interactive 5-fluorouracil PK/PD simulator with nonlinear two-compartment pharmacokinetics, DPD activity adjustment, and Friberg myelosuppression modeling. 5-FU is a fluoropyrimidine antimetabolite that inhibits thymidylate synthase and also disrupts RNA and DNA synthesis in proliferating tumor cells. Built for exposure-guided dosing in colorectal and other gastrointestinal cancers using FOLFOX, FOLFIRI, and continuous infusion regimens.
Drug Overview
Clinical Context
- Molecular Target
- Thymidylate synthase, with RNA and DNA misincorporation effects
- Drug Class
- Fluoropyrimidine antimetabolite
- Therapeutic Area
- Oncology
- Indication
- Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens
- Route of Administration
- IV infusion
Model Information
- Model Type
- PK/PD model with 2-compartment Michaelis-Menten PK and Friberg myelosuppression PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model with 2-compartment Michaelis-Menten PK and Friberg myelosuppression PD model characterizes the pharmacokinetics of this fluoropyrimidine antimetabolite following iv infusion administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses PK simulator?
This is a free, interactive pharmacokinetic simulator for 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses used in Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses belong to?
5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses is classified as a Fluoropyrimidine antimetabolite that targets Thymidylate synthase, with RNA and DNA misincorporation effects. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV infusion administration of 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PK/PD model with 2-compartment Michaelis-Menten PK and Friberg myelosuppression PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Docetaxel
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer
Capecitabine and 5-FU
Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma
PBPK-PD of ADCs
Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy
Sacituzumab Govitecan (Trodelvy)
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload
Ready to Simulate?
Launch the 5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community